Technical Analysis for EPRX - Eupraxia Pharmaceuticals Inc

Grade Last Price % Change Price Change
C 6.08 -1.46% -0.090
EPRX closed up 1.15 percent on Thursday, April 15, 2021, on 9 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A N/A Up
Historical EPRX trend table...

Date Alert Name Type % Chg
Stochastic Sell Signal Bearish -1.46%
Narrow Range Bar Range Contraction -1.46%
NR7 Range Contraction -1.46%
Inside Day Range Contraction -1.46%
Wide Bands Range Expansion -1.46%
Overbought Stochastic Strength -1.46%
Hot IPO Pullback Bullish Swing Setup -0.33%
Pocket Pivot Bullish Swing Setup -0.33%
Wide Bands Range Expansion -0.33%
Overbought Stochastic Strength -0.33%
Older End-of-Day Signals for EPRX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Fell Below Previous Day's Low about 4 hours ago
Down 1% about 4 hours ago
Up 1% 1 day ago
Possible Pocket Pivot 2 days ago
Up 3% 2 days ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Eupraxia Pharmaceuticals Inc Description

Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidate, EP-104IAR, that is in a Phase II clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis, as well as under development for treatment of canine and equine osteoarthritis. Its products in development also include EP-201, a product candidate for prophylaxis of post-surgical infections; and EP-105, an extended-release product candidate for the local delivery of anesthetics to treat post-surgical pain. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was founded in 2012 and is headquartered in Victoria, Canada.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Pain Biotechnology Life Sciences Arthritis Osteoarthritis Skeletal Disorders

Is EPRX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 7.19
52 Week Low 4.6
Average Volume 26,243
200-Day Moving Average 0.000
50-Day Moving Average 0.000
20-Day Moving Average 5.524
10-Day Moving Average 5.689
Average True Range 0.435
ADX 0.0
+DI 21.128
-DI 20.281
Chandelier Exit (Long, 3 ATRs ) 5.621
Chandelier Exit (Short, 3 ATRs ) 5.904
Upper Bollinger Band 6.641
Lower Bollinger Band 4.406
Percent B (%b) 0.79
BandWidth 40.456
MACD Line 0.020
MACD Signal Line -0.122
MACD Histogram 0.1415
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.245
Resistance 3 (R3) 6.250 6.230 6.233
Resistance 2 (R2) 6.230 6.211 6.228 6.228
Resistance 1 (R1) 6.200 6.199 6.195 6.195 6.224
Pivot Point 6.180 6.180 6.178 6.178 6.180
Support 1 (S1) 6.150 6.161 6.145 6.145 6.116
Support 2 (S2) 6.130 6.149 6.128 6.112
Support 3 (S3) 6.100 6.130 6.108
Support 4 (S4) 6.095